Francesco Carrozza

1.7k total citations
26 papers, 384 citations indexed

About

Francesco Carrozza is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Francesco Carrozza has authored 26 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Francesco Carrozza's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Francesco Carrozza is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Francesco Carrozza collaborates with scholars based in Italy, United States and Spain. Francesco Carrozza's co-authors include Ciro Gallo, Cesare Gridelli, Luigi Manzione, Alessandra Bearz, Sergio Robbiati, Francesco Ferraù, Ugo De Giorgi, Francesco Perrone, Paolo Maione and Matteo Santoni and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Francesco Carrozza

26 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesco Carrozza Italy 10 230 183 63 58 58 26 384
L Brancaccio Italy 9 226 1.0× 271 1.5× 63 1.0× 39 0.7× 55 0.9× 17 388
L. Isa Italy 8 243 1.1× 349 1.9× 68 1.1× 64 1.1× 36 0.6× 18 484
Marco Filetti Italy 12 121 0.5× 158 0.9× 15 0.2× 57 1.0× 70 1.2× 38 319
Fumihiko Hojo Japan 12 188 0.8× 199 1.1× 11 0.2× 82 1.4× 79 1.4× 20 414
C. Roemer-Bécuwe France 8 63 0.3× 152 0.8× 33 0.5× 37 0.6× 105 1.8× 15 346
David D. Biggs United States 10 71 0.3× 231 1.3× 17 0.3× 238 4.1× 54 0.9× 20 570
Yoshitaka Ogata Japan 11 132 0.6× 174 1.0× 10 0.2× 20 0.3× 40 0.7× 26 272
Frederick M. Schnell United States 8 136 0.6× 199 1.1× 16 0.3× 192 3.3× 51 0.9× 17 481
Aydın Yavuz Türkiye 10 130 0.6× 81 0.4× 8 0.1× 92 1.6× 18 0.3× 33 326
Suzanna Bota France 10 192 0.8× 170 0.9× 10 0.2× 94 1.6× 18 0.3× 21 318

Countries citing papers authored by Francesco Carrozza

Since Specialization
Citations

This map shows the geographic impact of Francesco Carrozza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Carrozza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Carrozza more than expected).

Fields of papers citing papers by Francesco Carrozza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Carrozza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Carrozza. The network helps show where Francesco Carrozza may publish in the future.

Co-authorship network of co-authors of Francesco Carrozza

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Carrozza. A scholar is included among the top collaborators of Francesco Carrozza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Carrozza. Francesco Carrozza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Antonuzzo, Lorenzo, Rosa Tambaro, Sebastiano Buti, et al.. (2024). READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma. SHILAP Revista de lepidopterología. 5. 100068–100068. 4 indexed citations
2.
Massari, Francesco, Vincenzo Di Nunno, Matteo Santoni, et al.. (2019). Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology. 142. 141–152. 14 indexed citations
3.
Carrozza, Francesco, Matteo Santoni, Francesco Piva, et al.. (2018). Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. Critical Reviews in Oncology/Hematology. 131. 1–6. 8 indexed citations
4.
Giulietti, Matteo, Matteo Santoni, Alessia Cimadamore, et al.. (2018). Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. Frontiers in Oncology. 8. 221–221. 20 indexed citations
5.
Santoni, Matteo, Francesco Massari, Francesco Piva, et al.. (2018). Tivozanib for the treatment of renal cell carcinoma. Expert Opinion on Pharmacotherapy. 19(9). 1021–1025. 16 indexed citations
6.
Conteduca, Vincenza, Orazio Caffo, Cristian Lolli, et al.. (2017). Long‐term clinical impact of PSA surge in castration‐resistant prostate cancer patients treated with abiraterone. The Prostate. 77(9). 1012–1019. 7 indexed citations
7.
Ripabelli, Giancarlo, et al.. (2017). Asbestos Exposures, Mesothelioma Incidence and Mortality, and Awareness by General Practitioners in the Molise Region, Central Italy. Journal of Occupational and Environmental Medicine. 60(2). e90–e97. 2 indexed citations
8.
Burgio, Salvatore Luca, Vincenza Conteduca, Francesco Carrozza, et al.. (2014). PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 13(1). 39–43. 53 indexed citations
9.
Clavarezza, Matteo, Giorgio Mustacchi, Andrea Casadei‐Gardini, et al.. (2012). Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer. 12(1). 216–216. 6 indexed citations
10.
Caravatta, L., Francesco Deodato, Gabriella Macchia, et al.. (2012). A Phase I Study of Short-Course Accelerated Whole Brain Radiation Therapy for Multiple Brain Metastases. International Journal of Radiation Oncology*Biology*Physics. 84(4). e463–e468. 11 indexed citations
11.
12.
Maïo, Massimo Di, Alessandro Morabito, Santi Barbera, et al.. (2010). Education level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials.. Journal of Clinical Oncology. 28(15_suppl). 6124–6124. 1 indexed citations
13.
14.
15.
16.
Gridelli, Cesare, Manlio Mencoboni, Francesco Carrozza, et al.. (2008). Cetuximab (C) and gemcitabine (G) in elderly or adult PS2 advanced non small-cell lung cancer (NSCLC) patients (pts): The CALC1 randomised phase II trials. Journal of Clinical Oncology. 26(15_suppl). 8117–8117. 6 indexed citations
17.
Giuliani, Francesco, S. Romito, Evaristo Maiello, et al.. (2008). Epirubicin, taxotere and fluorouracil modulated by folinic acid in the treatment of advanced gastric cancer: A phase II study of the Gruppo Oncologico dell’ Italia Meridionale (GOIM). European Journal of Cancer Supplements. 6(14). 107–112. 1 indexed citations
18.
Gridelli, Cesare, Paolo Maione, Alfonso Illiano, et al.. (2007). Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The MILES-2P Studies. Journal of Clinical Oncology. 25(29). 4663–4669. 60 indexed citations
19.
Ianniello, Giovanni Pietro, Michele Orditura, Antônio Rossi, et al.. (2001). Gemcitabine plus epirubicin in advanced pancreatic cancer: A phase II multicenter trial. Oncology Reports. 8(5). 1111–5. 4 indexed citations
20.
Aiello, Alexandra, et al.. (1990). [Lymphocyte subpopulations and the soluble interleukin-2 receptor in Hashimoto's thyroiditis and subacute thyroiditis].. PubMed. 133(6). 401–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L Brancaccio Breakdown of academic impact, for papers by L. Isa Breakdown of academic impact, for papers by Marco Filetti Breakdown of academic impact, for papers by Fumihiko Hojo Breakdown of academic impact, for papers by C. Roemer-Bécuwe Breakdown of academic impact, for papers by David D. Biggs Breakdown of academic impact, for papers by Yoshitaka Ogata Breakdown of academic impact, for papers by Frederick M. Schnell Breakdown of academic impact, for papers by Aydın Yavuz Breakdown of academic impact, for papers by Suzanna Bota
Rankless by CCL
2026